Using advanced imaging to predict lymph node spread in high-risk prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of 18F-rhPSMA-7.3 PET/MRI imaging in predicting lymph node metastasis in patients with localized high-risk prostate cancer prior to undergoing radical prostatectomy. The study aims to assess the diagnostic accuracy of this imaging technique, including its specificity and predictive values for lymph node positivity. Patients will receive the imaging scan and be monitored for biochemical recurrence post-surgery. The trial includes a follow-up period to track outcomes related to prostate-specific antigen levels.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male subjects ≥ 30 and ≤ 85 years old
* Primary diagnosis of prostate cancer selected for surgical intervention (radical prostatectomy with extended lymph node dissection)
* Primary diagnosis of untreated American Urological Association (AUA) guidelines high-risk localized prostate cancer, hormone-naïve prostate cancer via contrast enhanced prostate MRI + tissue sampling
* Planned elective radical prostatectomy with extended pelvic lymph node dissection
* Clinical oligometastatic disease with ≤ 3 nodes positive on preoperative standard of care imaging of prostate region within 6 months of surgery
* Patient agrees to comply with the investigator instructions
* Patient agrees to comply with the follow-up surveillance schedule
* Have ability to provide full written consent

Exclusion Criteria:

* High-risk cancer planned for neoadjuvant therapy
* Patients with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study
* Patients that have had prior hormonal therapy such as Lupron or oral antiandrogens ≤ 12 weeks prior to registration
* Clinical oligometastatic disease with \> 3 nodes positive preoperative standard of care imaging of prostate region
* Previous history of pelvic radiation
* Patients with obesity defined as body mass index (BMI) \> 40 kg/m\^2
* History of prior laparoscopic inguinal hernia repair with mesh
* Scheduled at the time of screening to undergo chemotherapy, radiation, hormone therapy, or open surgery during the study period
* Inability to lie still for 75 minutes during 18F-rhPSMA-7.3 PSMA PET-MRI imaging
* Any neurologic disorder or psychiatric disorder that might confound postsurgical assessments
* Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment
* Received administration of an investigational drug within 30 days prior to study registration, and/or has planned administration of another investigational product or procedure during participation in this study

Where it's running

• Mayo Clinic in Florida
  Jacksonville, Florida, United States Recruiting

Study contacts

• Principal investigator: Ram A. Pathak, MD — Mayo Clinic
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exercise after pelvic radiation to see if it lowers colorectal cancer risk

  This study tests whether regular walking therapy after pelvic radiation for prostate cancer can influence markers of colorectal cancer in colon tissue and blood.

  Recruiting at 2 sites City of Hope Medical Center · Duarte, California and 1 other locations · NCT07790718

• Wrapping nerves with a multi-layer perinatal tissue graft during prostate removal

  This trial will test whether wrapping the nerves with a multi-layer perinatal tissue allograft during nerve-sparing robotic prostate removal helps men with localized prostate cancer keep erectile and urinary function.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT06940271

• Testosterone therapy for men with low testosterone and localized prostate cancer on active surveillance

  This study is testing if testosterone therapy can help men with low testosterone and localized prostate cancer feel better and stay safe while they are being monitored for their cancer.

  Recruiting Phase 4 Roswell Park Cancer Institute · Buffalo, New York · NCT06733350

• High-dose vitamin D for bone health in older prostate cancer patients on hormone therapy

  This study is testing if high-dose vitamin D can help older prostate cancer patients on hormone therapy keep their bones strong and reduce the risk of falls and fractures.

  Recruiting at 51 sites Phase 3 University of Rochester · Newark, Delaware and 50 other locations · NCT05838716

• MRI or CT planning to guide high-dose-rate prostate brachytherapy

  This trial tests whether adding an MRI to CT-based treatment planning for HDR prostate brachytherapy changes urinary side effects in men with localized prostate cancer.

  Recruiting at 3 sites Emory University · Atlanta, Georgia and 2 other locations · NCT07859722

• Image-guided adaptive stereotactic body radiation therapy for localized prostate cancer

  This trial tests whether daily, real-time adaptive image-guided SBRT causes fewer urinary and other side effects than standard non-adaptive SBRT for men with localized prostate cancer.

  Recruiting Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07276438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.